T&R Biofab Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-7,679	-13,419
Depreciation & Amortization	2,404	2,156
Loss (Gain) From Sale of Assets	5.8	0.14
Asset Writedown & Restructuring Costs	-	195.49
Loss (Gain) From Sale of Investments	517.37	-5.26
Stock-Based Compensation	792.02	1,347
Provision & Write-off of Bad Debts	792.12	542.03
Other Operating Activities	-5,237	2,105
Change in Accounts Receivable	-531.04	-843.53
Change in Inventory	-612.32	361.88
Change in Accounts Payable	-1,070	-1.18
Change in Unearned Revenue	46.9	-
Change in Other Net Operating Assets	-1,162	597.43
Operating Cash Flow	-11,733	-6,963
Capital Expenditures	-2,576	-12,493
Cash Acquisitions	-6,453	-
Sale (Purchase) of Intangibles	-232.19	-237.02
Investment in Securities	22,726	-25,002
Other Investing Activities	145.27	138.24
Investing Cash Flow	11,689	-37,515
Long-Term Debt Issued	17,200	34,000
Long-Term Debt Repaid	-25,549	-6,478
Net Debt Issued (Repaid)	-8,349	27,522
Issuance of Common Stock	34.18	2,024
Other Financing Activities	0	38.42
Financing Cash Flow	-3,515	29,585
Foreign Exchange Rate Adjustments	2.43	-0.25
Miscellaneous Cash Flow Adjustments	0	-0
Net Cash Flow	-3,556	-14,894
Free Cash Flow	-14,309	-19,456
Free Cash Flow Margin	-293.60%	-374.22%
Free Cash Flow Per Share	-664.29	-917.58
Cash Interest Paid	860.99	191.13
Cash Income Tax Paid	3.99	-14.54
Levered Free Cash Flow	-17,632	-
Unlevered Free Cash Flow	-17,631	-
Change in Net Working Capital	9,555	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.